Evidence map›Paper›PMID 40143392›Full record

ArticleCurrent drug safety2026

Certolizumab-Induced Urticarial Vasculitis: A Case Report.

Bouraoui Ouni, Ferdaous Chahed, Raoudha Slim, Baheddine Dridi, Malek Sassi, Badereddine Sriha, Nedia Ghariani, Nesrine Bensayed, Neila Fathallah

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Current drug safety, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Treatment Challenges in Refractory Urticarial Vasculitis.Clinical, cosmetic and investigational dermatology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Bouraoui OuniDepartment of Pharmacology. Faculty of Medicine, University of Sousse, Sousse, Tunisia.ORCID 0000-0001-7809-1748
Ferdaous ChahedDepartment of Pharmacology. Faculty of Medicine, University of Sousse, Sousse, Tunisia.
Raoudha SlimDepartment of Pharmacology. Faculty of Medicine, University of Sousse, Sousse, Tunisia.
Baheddine DridiFaculty of Pharmacy, University of Monastir, Monastir, Tunisia.
Malek SassiFaculty of Pharmacy, University of Monastir, Monastir, Tunisia.
Badereddine SrihaDepartment of Anatomopathology, Farhat Hached Academic Hospital, Sousse, Tunisia.
Nedia GharianiDepartment of Dermatology, Farhat Hached Academic Hospital, Sousse, Tunisia.
Nesrine BensayedDepartment of Hematology, Farhat Hached Academic Hospital, Sousse, Tunisia.
Neila FathallahDepartment of Pharmacology. Faculty of Medicine, University of Sousse, Sousse, Tunisia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionCertolizumab (CZ) is a tumour necrosis factor-α (TNF-α) blocking agent with excellent efficiency in rheumatoid arthritis (RA). Urticarial vasculitis (UV) induced by CZ is a rare side effect. Herein, we describe a patient with UV probably induced by CZ therapy. CASE PRESENTATION: A 33-year-old female with RA was treated with methotrexate and corticosteroids, which resulted in no improvement. The patient was switched to CZP, and one week later, she developped urticaria (erythematous and edematous plaques). The diagnosis of urticarial vasculitis related to CZ was suspected. The results of microbiological and autoimmunity tests ruled out other causes of vasculitis. The diagnosis of CZ-induced-UV was retained (Naranjo's score: 5). CZ was withdrawn, which led to rapid resolution of skin lesions.

conclusionWith the increasing use of CZ, physicians should be aware of the possibility of UV associated with CZ.

Indexed as

Antirheumatic AgentsCertolizumab PegolUrticariaVasculitisAdultArthritis, RheumatoidFemaleHumansAntirheumatic AgentsCertolizumab Pegoladverse drug reaction.case reportCertolizumabinflammatory diseasespharmacovigilancerheumatoid arthritistumour necrosis factor-αvasculitis

Identifiers

PMID40143392

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.